The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1062524/full |
| _version_ | 1797950678788734976 |
|---|---|
| author | Sunil Girish Iyer Sunil Girish Iyer Laila Elias Michele Stanchina Michele Stanchina Justin Watts Justin Watts |
| author_facet | Sunil Girish Iyer Sunil Girish Iyer Laila Elias Michele Stanchina Michele Stanchina Justin Watts Justin Watts |
| author_sort | Sunil Girish Iyer |
| collection | DOAJ |
| description | The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL. |
| first_indexed | 2024-04-10T22:18:55Z |
| format | Article |
| id | doaj.art-a0cf548b97e2455182b0d2d900860b72 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T22:18:55Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a0cf548b97e2455182b0d2d900860b722023-01-18T05:51:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011210.3389/fonc.2022.10625241062524The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directionsSunil Girish Iyer0Sunil Girish Iyer1Laila Elias2Michele Stanchina3Michele Stanchina4Justin Watts5Justin Watts6Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, United StatesSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United StatesUniversity of Miami Miller School of Medicine, Miami, FL, United StatesDepartment of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, United StatesSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United StatesDepartment of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, United StatesSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United StatesThe transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL.https://www.frontiersin.org/articles/10.3389/fonc.2022.1062524/fullacute promyelocytic leukemiaall-trans retinoic acid (ATRA)arsenic trioxide (ATO)differentiation syndromedisseminated intravascular coagulation (DIC)coagulopathy |
| spellingShingle | Sunil Girish Iyer Sunil Girish Iyer Laila Elias Michele Stanchina Michele Stanchina Justin Watts Justin Watts The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions Frontiers in Oncology acute promyelocytic leukemia all-trans retinoic acid (ATRA) arsenic trioxide (ATO) differentiation syndrome disseminated intravascular coagulation (DIC) coagulopathy |
| title | The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions |
| title_full | The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions |
| title_fullStr | The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions |
| title_full_unstemmed | The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions |
| title_short | The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions |
| title_sort | treatment of acute promyelocytic leukemia in 2023 paradigm advances and future directions |
| topic | acute promyelocytic leukemia all-trans retinoic acid (ATRA) arsenic trioxide (ATO) differentiation syndrome disseminated intravascular coagulation (DIC) coagulopathy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1062524/full |
| work_keys_str_mv | AT sunilgirishiyer thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT sunilgirishiyer thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT lailaelias thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT michelestanchina thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT michelestanchina thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT justinwatts thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT justinwatts thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT sunilgirishiyer treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT sunilgirishiyer treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT lailaelias treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT michelestanchina treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT michelestanchina treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT justinwatts treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections AT justinwatts treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections |